Diclofenac in Wastewater: Why EU Rules Target Pharma and What It Means for Water Safety

Pharmaceutical pollution is emerging as a significant threat to Europe’s water systems, with diclofenac—a widely used painkiller—at the center of growing regulatory scrutiny. New findings show that medicines and cosmetics contribute to over 90% of the toxicity in wastewater after initial treatment, prompting the European Union to mandate advanced treatment stages funded largely by the industries responsible.

The Urban Wastewater Treatment Directive now requires the pharmaceutical and cosmetics sectors to cover up to 80% of the costs for a fourth treatment stage designed to remove micropollutants. This measure follows evidence that conventional treatment plants fail to break down many synthetic compounds, allowing substances like diclofenac, antidepressants, and blood pressure medications to persist in treated water.

According to the European Commission, pharmaceuticals and personal care products are responsible for 92% of the residual toxicity in wastewater following the first three treatment stages. This conclusion underpins the polluter-pays principle driving the new regulation. While industry groups have challenged the accuracy of these figures, water experts maintain that the overall scale of contamination is significant, even if precise measurements vary due to factors like rainfall and hospital connectivity.

EurEau, the European federation of national water service associations, acknowledges data variability but affirms that the pharmaceutical industry’s contribution remains substantial. With over 40,000 treatment plants across the EU, achieving complete precision in monitoring is difficult, yet the organization confirms that the general magnitude of pharmaceutical pollution aligns with observed environmental impacts.

Compounding concerns, the European Environment Agency reported in 2024 that 55% of EU surface waters had poor chemical status—a condition to which pharmaceutical pollution is a major contributor. Micropollutants such as diclofenac are particularly troubling because they are not fully metabolized by biological treatment processes and can accumulate in rivers, lakes, and groundwater.

Research published in Nature highlights the environmental risk of diclofenac in European groundwaters. Although measured concentrations were found to be below harmful levels for certain species like the groundwater crustacean Proasellus lusitanicus, the study emphasizes that risk assessments must consider multiple species’ sensitivities. Scientists recommend establishing an environmental quality standard for diclofenac in groundwater at 5 ng/L to ensure precautionary protection of fragile subsurface ecosystems.

In the Netherlands, water authorities have called for stricter national and EU-level approaches to diclofenac, urging revisions to the Water Framework Directive to better address persistent organic pollutants. Their advocacy reflects broader concerns that current regulations may not adequately safeguard long-term water quality.

Facilities like the Schönerlinde wastewater treatment plant near Berlin illustrate the scale of the challenge. Serving 850,000 residents, the plant relies on microbial activity to break down waste but cannot remove many synthetic chemicals. A complex mixture of pharmaceuticals—including painkillers, antidepressants, and antihypertensives—passes through treatment largely unchanged.

A large-scale study of European rivers detected 504 harmful substances, 175 of which were pharmaceuticals. While individual concentrations are low, experts warn that the combined effect of this “chemical cocktail” poses uncertain risks to aquatic life and potentially to human health through prolonged exposure.

Despite improvements in water quality over the past four decades, officials agree that more action is needed. The push for advanced wastewater treatment represents a critical step toward reducing pharmaceutical pollution, though its success depends on industry cooperation, technological innovation, and sustained regulatory enforcement.

As Europe moves forward with these measures, the focus remains on balancing public health needs with environmental protection—ensuring that life-saving medications do not come at the cost of contaminating the water systems communities depend on.